Ian Mortimer, PRESIDENT & CEO at Xenon Pharmaceuticals Inc. (XENE), sold 50,410 shares at $46.32 ($2.3M) on 2025-12-08, disclosed to the SEC on 2025-12-09.
Scheduled sale ($2.3M) by PRESIDENT & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.03 | 14,375 | $647K | 28.3% |
| 2 | $45.03 | 14,375 | $647K | 28.3% |
| 3 | $45.59 | 8,820 | $402K | 17.6% |
| 4 | $45.59 | 8,820 | $402K | 17.6% |
| 5 | $46.32 | 2,010 | $93K | 4.1% |
| 6 | $46.32 | 2,010 |
| $93K |
| 4.1% |
| Total | $45.33 avg | 50,410 | $2.3M | 100% |
| Filing → |
| XENE | SELL | 2026-03-11 | $17.6M | — | Filing → |
| XENE | SELL | 2026-01-02 | $1.8M | — | Filing → |
| XENE | SELL | 2025-12-03 | $4K | — | Filing → |